Fig. 2From: Molecular Evidence-Based Use of Bone Resorption-Targeted Therapy in Prostate Cancer Patients at High Risk for Bone Involvement Schematic representation of the main pharmacologic cell targets and pathophysiologic mechanisms targeted by ASF therapy (practically an anti-IGF-I bioavailability therapy) using the combination of somatostatin analog and dexamethasone in the clinical setting of hormone refractory prostate cancer. Back to article page